These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23868553)

  • 1. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis.
    Johnson DR; Leeper HE; Uhm JH
    Cancer; 2013 Oct; 119(19):3489-95. PubMed ID: 23868553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
    Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional probability of long-term survival in glioblastoma: a population-based analysis.
    Johnson DR; Ma DJ; Buckner JC; Hammack JE
    Cancer; 2012 Nov; 118(22):5608-13. PubMed ID: 22569786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
    Reardon DA; Herndon JE; Peters KB; Desjardins A; Coan A; Lou E; Sumrall AL; Turner S; Lipp ES; Sathornsumetee S; Rich JN; Sampson JH; Friedman AH; Boulton ST; Bigner DD; Friedman HS; Vredenburgh JJ
    Br J Cancer; 2012 Oct; 107(9):1481-7. PubMed ID: 23037712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis.
    Wagner CC; Held U; Kofmehl R; Battegay E; Zimmerli L; Hofer S
    Acta Oncol; 2014 Apr; 53(4):572-5. PubMed ID: 24219539
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
    Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
    Wachtel MS; Yang S
    Cancer Med; 2014 Jun; 3(3):660-6. PubMed ID: 24610705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
    Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab as first-line therapy for glioblastoma.
    Piccioni D; Lai A; Nghiemphu P; Cloughesy T
    Future Oncol; 2012 Aug; 8(8):929-38. PubMed ID: 22894667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
    Hofer S; Elandt K; Greil R; Hottinger AF; Huber U; Lemke D; Marosi C; Ochsenbein A; Pichler J; Roelcke U; Weder P; Zander T; Wick W; Weller M
    Acta Oncol; 2011 Jun; 50(5):630-5. PubMed ID: 21495907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for the treatment of glioblastoma.
    Chowdhary S; Chamberlain M
    Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.